Lexeo Therapeutics (LXEO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Voting matters and shareholder proposals
Election of Paula HJ Cholmondeley, Brenda Cooperstone, and R. Nolan Townsend as Class III directors is proposed, with board recommendation to vote in favor.
Ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is recommended.
Proxyholders are authorized to vote on any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Three nominees are presented for election as Class III directors, indicating a staggered board structure.
Audit committee and external auditor matters
KPMG LLP is proposed for ratification as the independent auditor for the next fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Lexeo Therapeutics
- Gene therapies for rare cardiac diseases show strong clinical progress and 2026 milestones ahead.LXEO
Corporate presentation11 May 2026 - LX2006 pivotal trial advances, strong cash runway, and reduced net loss highlight Q1 2026.LXEO
Q1 202611 May 2026 - Annual meeting to elect directors, ratify auditor, and reinforce governance and shareholder rights.LXEO
Proxy filing30 Apr 2026 - Gene therapies show robust efficacy and safety in FA and PKP2-ACM, with pivotal trials ahead.LXEO
Oppenheimer 36th Annual Healthcare Life Sciences Conference7 Apr 2026 - Gene therapies for rare cardiac diseases show strong clinical progress and pivotal trials ahead.LXEO
Corporate presentation30 Mar 2026 - LX2006 and LX2020 advance with strong interim data and cash runway into 2028.LXEO
Q4 202530 Mar 2026 - Pivotal studies for FA and PKP2 advance with strong clinical data, robust manufacturing, and solid financials.LXEO
Leerink Global Healthcare Conference 202610 Mar 2026 - Gene therapy programs show strong efficacy and safety, with key regulatory updates due in 2026.LXEO
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - Gene therapy programs show promising biomarker and clinical results, with major data updates ahead.LXEO
2024 Cantor Fitzgerald Global Healthcare Conference3 Feb 2026